CKD-712
CKD-712 is an orally active multi-target tetrahydroisoquinoline derivatived and a potent inhibitor of the NF-κB pathway. CKD-712 selectively inhibits MMP-9 with no effect on MMP-2, downregulates the expression of TNF-α, IL-6, cyclin A, cyclin B, CDK-1 and other proteins, and activates the PI3K/Akt signaling pathway. CKD-712 blocks the activation and nuclear translocation of NF-κB, downregulates inflammatory factors and pro-tumor metastatic proteins, and induces G2/M phase arrest in tumor cells and thereby inhibits the invasion of cancer cells. CKD-712 can be used for the research of sepsis, myocardial ischemia-reperfusion injury and non-small cell lung cancer.
For research use only. We do not sell to patients.
- CAS No.: 626252-75-3
- Formula: C20H19NO2
- Molecular Weight:305.37
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
|
NF-κB |
MMP-9 |
IL-6 |
Cdk1/cyclin B |
CDK1/cyclin A |
PI3K |
Akt |
In Vitro
CKD-712 (5-30 μg/mL; 48 h) dose-dependently suppresses proliferation of A549 human lung adenocarcinoma cells, with 30 μg/mL inhibiting proliferation by 60% without inducing cell death[2].
CKD-712 (30-50 µg/ml; 48 h) induces G2/M cell cycle arrest in A549 cells[2].
CKD-712 (30 µg/ml; 48 h) suppresses cyclin A, cyclin B and CDK-1 expression in A549 human lung cancer cells[2].
CKD-712 (30 µg/ml; 48 h) dose-dependently inhibits mitosis in A549 human lung carcinoma cells[2].
CKD-712 (20 µg/ml; 12 h, 24 h) inhibits adenocarcinoma cell growth[2].
CKD-712 (10 µg/ml; 1 h; pre-incubation) inhibits TNF-α-induced NF-κB activation in A549 human lung carcinoma cells[2].
CKD-712 (5-30 µg/ml; 24 h) suppressed proteins involved in proliferation, anti-apoptosis, and angiogenesis in A549 human lung carcinoma cells[2].
CKD-712 (30 µg/ml; 48 h) dose-dependently inhibits MMP-9 activity in A549 human lung carcinoma cells without affecting MMP-2 activity[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:A549 human lung carcinoma cells
-
Concentration:5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL
-
Incubation Time:48 h
-
Result:Significantly suppressed cell proliferation in a dose-dependent manner up to 60% at 30 μg/mL.
-
Cell Line:A549 human lung carcinoma cells
-
Concentration:5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL
-
Incubation Time:48 h
-
Result:Suppressed the expression of cyclin A, cyclin B and CDK-1 proteins.
-
Cell Line:A549 human lung carcinoma cells
-
Concentration:5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL
-
Incubation Time:24 h
-
Result:Inhibited TNF-α-induced NF-κB p65 nuclear translocation; suppressed proteins involved in proliferation, anti-apoptosis, and angiogenesis including Mcl-1, COX-2, XIAP, and VEGF in A549 cells.
-
Cell Line:A549 human lung carcinoma cells
-
Concentration:5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL
-
Incubation Time:24 h
-
Result:Inhibited A549 cell invasion in a dose-dependent manner.
-
Cell Line:A549 human lung carcinoma cells
-
Concentration:20 μg/mL
-
Incubation Time:12 h, 24 h
-
Result:Inhibited A549 cell migration as evidenced by controlled wound closure compared to test.
-
Cell Line:A549 human lung carcinoma cells
-
Concentration:5 μg/mL, 10 μg/mL, 20 μg/mL, 30 μg/mL
-
Incubation Time:48 h
-
Result:Induced marked cell cycle changes with an increase in the fraction of cells in G2/M, indicating significant G2/M cell death.
Parmacokinetics
In Vivo
CKD-712 (1-3 mg/kg/day; i.p.; once daily; 4 total doses) improves survival in CLP-induced polymicrobial septic mice, with a 50% survival rate observed at 1 mg/kg/day administered over 4 days[1].
CKD-712 (2.5-20 mg/kg; i.p.; two doses (24 hours and 1 hour pre-LPS)) dose-dependently reduces markers of liver and kidney injury in LPS-induced DIC rats, with the greatest reduction in GOT (117.8 U/L) and BUN (11.8 mg/dL) observed at 20 mg/kg[1].
CKD-712 (20 mg/kg; i.p.; two doses (24 hours and 1 hour pre-LPS)) protects against LPS-induced histological damage to the liver and lung in DIC rats, reducing inflammatory cell infiltration and tissue necrosis[1].
CKD-712 (1-20 mg/kg; i.p.; single dose) dose-dependently improves survival in LPS-induced septic mice, with up to 92% survival observed at 5 and 10 mg/kg when administered 30 minutes pre-LPS[1].
CKD-712 (5-20 mg/kg; i.p.; single dose; 30 min pre-zymosan) improves survival in zymosan-induced septic mice, with a 67% survival rate observed at 20 mg/kg when administered 30 minutes pre-zymosan[1].
CKD-712 (2.5-20 mg/kg; i.p.; two doses (24 hours and 1 hour pre-LPS)) dose-dependently suppresses LPS-induced systemic inflammation in DIC rats, with the greatest reduction in TNF-α (85.5 pg/mL) observed at 10 mg/kg[1].
CKD-712 (20 mg/kg; i.p.; two doses (24 hours and 1 hour pre-LPS)) inhibits LPS-induced NF-κB translocation to the nucleus in lung pneumocytes of DIC rats, reducing pro-inflammatory signaling[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:ICR (male, 25-30 g, zymosan-induced endotoxemia sepsis model)[1]
-
Dosage:5, 10, 20 mg/kg
-
Administration:Intraperitoneal (i.p.) single dose; 30 min pre-zymosan
-
Result:Achieved survival rates of 42%, 50%, and 67% at 5, 10, and 20 mg/kg respectively at 6 days post-zymosan (statistically significant at 20 mg/kg, p ≤ 0.05).
-
Animal Model:ICR (male, 25-30 g, LPS-induced hypothermia sepsis model)[1]
-
Dosage:1, 3, 10, 20 mg/kg
-
Administration:Intraperitoneal (i.p.) single dose; 30 min pre-LPS
-
Result:Prevented LPS-induced hypothermia, maintaining significantly higher mean rectal temperatures compared to vehicle controls at 5 and 7 hours post-LPS (p ≤ 0.05).
Enabled all groups to recover to normal temperatures by 23 hours post-LPS.
-
Animal Model:ICR (male, 25-30 g, CLP-induced polymicrobial sepsis model)[1]
-
Dosage:1, 3 mg/kg/day
-
Administration:Intraperitoneal (i.p.) once daily; 4 total doses (2 pre-surgery, 2 post-surgery)
-
Result:Improved final survival rates to 50% and 45% at 1 mg/kg/day and 3 mg/kg/day respectively, compared to 15% survival with CLP alone at 72 hours post-surgery.
Sprague-Dawley (SD) (male, 150–160 g, LPS-induced systemic inflammation Dlc model)
-
Animal Model:ICR (male, 25-30 g, LPS-induced endotoxemia sepsis model)[1]
-
Dosage:1, 3, 10, 20 mg/kg (4 hours post-LPS)
-
Administration:Intraperitoneal (i.p.) single dose
-
Result:Achieved survival rates of 33%, 40%, 40%, and 53% at 1, 3, 10, and 20 mg/kg respectively when administered 4 hours post-LPS.
-
Animal Model:ICR (male, 25-30 g, LPS-induced endotoxemia sepsis model)[1]
-
Dosage:2.5, 5, 10, 20 mg/kg (1 hour post-LPS)
-
Administration:Intraperitoneal (i.p.) single dose
-
Result:Achieved survival rates of 47%, 60%, 67%, and 67% at 1, 3, 10, and 20 mg/kg respectively when administered 1 hour post-LPS (statistically significant at 10, 20 mg/kg, p ≤ 0.05).
-
Animal Model:Sprague-Dawley (SD) (male, 150-160 g, LPS-induced septic organ injury Dlc model)[1]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal (i.p.); two doses (24 hours and 1 hour pre-LPS)
-
Result:Inhibited LPS-induced translocation of NF-κB from the cytoplasm to the nucleus of lung pneumocytes, with NF-κB remaining localized to the cytoplasm.
Reduced liver sinusoidal enlargement and inflammatory cell infiltration caused by LPS.
Reduced lung pneumocyte hypertrophy, inflammatory cell infiltration, and central necrosis caused by LPS.
-
Animal Model:Sprague-Dawley (SD) (male, 150–160 g, LPS-induced systemic inflammation Dlc model)[1]
-
Dosage:2.5, 5, 10, 20 mg/kg
-
Administration:Intraperitoneal (i.p.); two doses (24 hours and 1 hour pre-LPS)
-
Result:LPS-induced GOT, GPT, BUN, creatinine, TNF-α, and IL-6 levels were all reduced in a dose-dependent manner at 2.5, 5, 10, and 20 mg/kg respectively.
Chemical Information
-
CAS No. 626252-75-3
-
Molecular Weight 305.37
-
Formula C20H19NO2
-
SMILES
OC1=CC2=C([C@H](CC3=C(C=CC=C4)C4=CC=C3)NCC2)C=C1O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
RNA extraction experimental
By lysing cells, releasing RNA, and removing impurities such as proteins and DNA, high-purity RNA products are finally obtained. The commonly used traditional method is the guanidine isothiocyanate/phenol/chloroform method (Trizol), which is suitable for a variety of animal materials including animal tissues, microorganisms, cultured cells, etc., and most plant materials.
-
Cytoplasmic-Nuclear Fractionated Protein Extraction
Cytoplasmic-nuclear fractionated protein extraction separates soluble cytoplasmic proteins from nuclear-enriched proteins by mild plasma-membrane permeabilization, differential centrifugation, washing of nuclei, and extraction of nuclear proteins for downstream immunoblotting or related molecular analysis. The readout is the relative abundance of a protein in cytoplasmic and nuclear fractions, commonly assessed by western blotting together with compartment markers such as tubulin or pyruvate kinase for cytoplasm and lamin, nucleoporin, hnRNP, H2AX, or Lamin B for nuclear fractions.
-
Mitochondrial membrane-potential fluorescent assay
Mitochondrial membrane potential fluorescent assays estimate ΔΨm in living cells using lipophilic cationic dyes such as TMRM, TMRE, rhodamine 123, and JC-1, which accumulate in mitochondria according to membrane polarization; loss of signal after FCCP or CCCP treatment is interpreted as mitochondrial depolarization. TMRM/TMRE and rhodamine 123 are commonly used for semi-quantitative live-cell microscopy or flow cytometry, while JC-1 can report a shift from red aggregate fluorescence to green monomer fluorescence during depolarization; interpretation requires controls because dye concentration, quenching mode, cell type, dye efflux, and mitochondrial mass can affect fluorescence independently of ΔΨm.
-
Flow cytometric DNA-content cell-cycle staining
Flow cytometric DNA-content cell-cycle staining measures the fluorescence intensity of DNA-bound fluorochromes in single cells or nuclei to estimate DNA content distributions, allowing assignment of populations to G0/G1, S, and G2/M phases by DNA histogram deconvolution. Propidium iodide (PI) intercalates into DNA, and PI fluorescence is proportional to cellular DNA content when staining is performed under conditions that make DNA accessible and minimize non-DNA signal. Cells with G2/M DNA content are expected to show approximately twice the fluorescence intensity of G0/G1 cells, while S-phase cells occupy intermediate fluorescence values. PI-based DNA-content analysis can also detect cells with fractional DNA content, often reported as sub-G1, when DNA fragmentation and extraction during staining reduce retained DNA signal in apoptotic cells. DAPI is an alternative DNA fluorochrome for univariate DNA-content analysis, while bivariate approaches combining DNA content with proliferation
-
LPS-Induced Endotoxemia/Systemic Inflammation
Lipopolysaccharide (LPS)-induced endotoxemia is a widely used in vivo model of acute systemic inflammation in which LPS, a Gram-negative bacterial endotoxin, activates innate immune signaling primarily through TLR4, leading to rapid and transient induction of pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β in circulation and tissues. This cytokine surge is commonly used as a measurable readout of systemic inflammatory activation and immune dysregulation, and is typically assessed within hours after intraperitoneal LPS administration in mouse models of endotoxemia. The model captures key features of systemic inflammatory response syndrome, including cytokine release, immune cell activation, and downstream tissue responses, and has been used to evaluate anti-inflammatory interventions such as cytokine modulation, lipid mediators, and immune cell-targeting therapies.
-
Mitochondrial membrane-potential and mitochondrial mass staining
Mitochondrial membrane potential staining measures the electrochemical polarization across the mitochondrial inner membrane in live cells using lipophilic cationic fluorescent probes; early rhodamine-based work showed that selective mitochondrial dye accumulation is lost when the mitochondrial transmembrane potential is dissipated. JC-1 reports mitochondrial polarization by shifting from green monomer fluorescence to red J-aggregate fluorescence as dye concentration increases within energized mitochondria; therefore, the red/green fluorescence ratio is used as a relative readout of mitochondrial membrane potential. TMRE or TMRM staining provides a single-channel relative readout because these cationic rhodamine esters accumulate in polarized mitochondria, and lower fluorescence indicates reduced mitochondrial polarization when acquisition and dye-loading conditions are controlled. Mitochondrial mass staining is commonly performed with MitoTracker Green FM or related MitoTracker dyes as
-
Protocol for Cell Cycle
Cell-cycle analysis by flow cytometry measures DNA content in single cells to estimate the fraction of cells in G0/G1, S, and G2/M phases. Propidium iodide intercalates into DNA, and after RNA removal with RNase, fluorescence intensity reflects cellular DNA content: 2N cells are assigned to G0/G1, cells between 2N and 4N to S phase, and 4N cells to G2/M. DNA-content analysis alone cannot reliably separate G0 from G1 or G2 from M. Ki-67 can distinguish quiescent G0 cells from cycling cells, EdU or BrdU incorporation marks active DNA synthesis in S phase, and phospho-histone H3 staining identifies mitotic cells within the 4N population.
-
Cell invasion
Cell invasion is the ability of cells to migrate from one area to another via the extracellular matrix. Cell invasion is the response of normal and cancer cells to chemical and mechanical stimuli. Before migrating to a new region, the extracellular matrix is degraded by proteases within the cell. Cell invasion often occurs during wound repair, vascularization and inflammation, abnormal tissue invasion, and tumor cell metastasis.
-
Research Protocol for Inflammation-related Diseases
The NLRP3 inflammasome is a cytosolic innate immune signaling platform that integrates priming signals and danger-signal activation to promote caspase-1 activation, maturation of IL-1β and IL-18, and gasdermin D-mediated pyroptotic cell death. The core experimental logic is to determine whether inflammatory disease phenotypes are driven by increased NLRP3 expression, ASC-containing inflammasome assembly, caspase-1 cleavage, GSDMD cleavage, and extracellular release of IL-1β/IL-18 rather than by nonspecific cell injury alone. The pathway is strongly linked to inflammation-related disease phenotypes because monosodium urate crystals activate NALP3/NLRP3 inflammasome signaling in gout-like crystal inflammation, cholesterol crystals activate NLRP3 inflammasomes in atherogenesis models, and DSS-induced intestinal inflammation has been reported to involve NLRP3 inflammasome activity. However, experimental colitis studies also show context-dependent protective effects of NLRP3 inflammasome co
Purity & Documentation
References
[1]. Park JH, et al. Effects of the anti-sepsis drug, (S)-1-(α-naphthylmethyl)-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline (CKD-712), on mortality, inflammation, and organ injuries in rodent sepsis models. Arch Pharm Res. 2011 Mar;34(3):485-94. [Content Brief]
[2]. Lee WS, et al. Synthesized tetrahydroisoquinoline alkaloid exerts anticancer effects at least in part by suppressing NF-κB-regulated proteins in A549 human lung cancer cells. Oncol Rep. 2015;33(3):1141-1146. [Content Brief]
[3]. Chae JW, et al. Development of a LC-MS/MS method for the determination of CKD-712 in rat plasma: Application to a pharmacokinetic study in rats. J Chromatogr B Analyt Technol Biomed Life Sci. 2017;1061-1062:123-127. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Keywords
- CKD-712
- 626252-75-3
- CKD712
- CKD 712
- Drug Derivative
- NF-κB
- MMP
- TNF Receptor
- Interleukin Related
- Cyclin G-associated Kinase (GAK)
- CDK
- PI3K
- Akt
- NF-κB pathway inhibitor
- orally active
- A549 cells
- SD rats
- ICR mice
- LPS-induced sepsis model
- cecal ligation and puncture (CLP) model
- LPS-induced DIC model
- disseminated intravascular coagulation (DIC)
- zymosan-induced sepsis model mice
- non-small cell lung cancer
- anti-inflammatory
- anti-sepsis
- anti-thrombotic
- anti-cancer
- organ protection
- anti-apoptosis
- cell cycle arrest
- selective MMP-9 inhibition
- PI3K/Akt signaling activation
- TNF-α downregulation
- IL-6 downregulation
- Inhibitor
- inhibitor
- inhibit